Neurizon Therapeutics LimitedASX: NUZ

Positive feedback from FDA on strategy to lift clinical hold

· Issued by Neurizon Therapeutics Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The FDA has confirmed alignment with Neurizon's plan to conduct two preclinical pharmacokinetic studies, which have already been completed ahead of schedule. Neurizon plans to submit a Complete Response to the FDA in the near future, aiming to resolve the clinical hold and participate in the HEALEY ALS Platform Trial. The company remains committed to advancing treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Neurizon Therapeutics Limited on 6ix

Story so far

Earlier from Neurizon Therapeutics

Later from Neurizon Therapeutics

All Neurizon Therapeutics news releases